Illumina, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Schwab US Large Cap Growth ETF trades at $34.23. The key difference: Illumina, Inc. is trading nearer its 52-week high, Schwab US Large Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | SCHG | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $194.33 | $35.30 |
52-Week Low | $91.00 | $28.10 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
SCHG trades at $34.15, down 0.09% on the day, with a neutral technical signal. The ETF offers concentrated exposure to U.S. large-cap growth stocks, particularly in technology and AI-driven sectors, with a low 0.04% expense ratio. Recent institutional buying includes a 7.3% position increase by Alpha Zero LLC (Defense World, July 21, 2026).
Outlook remains mixed; strong fundamentals and AI growth potential support long-term gains, but high concentration in top holdings and elevated valuations near 32x P/E pose risks. Market sentiment is divided between bullish growth prospects and concerns over reliance on mega-cap performance.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →